DK0864649T3 - Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat - Google Patents

Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat

Info

Publication number
DK0864649T3
DK0864649T3 DK98202021T DK98202021T DK0864649T3 DK 0864649 T3 DK0864649 T3 DK 0864649T3 DK 98202021 T DK98202021 T DK 98202021T DK 98202021 T DK98202021 T DK 98202021T DK 0864649 T3 DK0864649 T3 DK 0864649T3
Authority
DK
Denmark
Prior art keywords
hepatitis
surface antigen
hep
virus
vaccine composition
Prior art date
Application number
DK98202021T
Other languages
English (en)
Inventor
Gonzalez Verena L Muzio
Galvez Marcelo Nazabal
Griego Marta De Jesu Gonzalez
Suarez Jose San Reafae Garcia
Zorrilla Filiberto Rosend Ayon
Maya Yair Quinones
Arias Eduardo Penton
Escobar Giuvel Fontirrochi
Iznaga Alejandro Beldarrain
Gonzalez Guillermo Juli Padron
Pena Arnaldo Garcia
Cruz Carlos Enrique Ruiz
Lopez Gladys Mabel Izquierdo
Martinez Luis Saturnin Herrera
Cano Carlos Antonio Duarte
Suarez Lilia Luisa Perez
La Riva Gustavo De
Avila Ramon Alexis Santiago
Meireles Rolando Paez
Fierro Alberto Agraz
Betancourt Raul Enrique Diaz
Albajes Victoria Ramirez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of DK0864649T3 publication Critical patent/DK0864649T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK98202021T 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat DK0864649T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU90155A CU22290A1 (es) 1990-10-08 1990-10-08 Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
EP91202615A EP0480525B1 (en) 1990-10-08 1991-10-07 Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B)

Publications (1)

Publication Number Publication Date
DK0864649T3 true DK0864649T3 (da) 2006-08-28

Family

ID=5459466

Family Applications (2)

Application Number Title Priority Date Filing Date
DK91202615T DK0480525T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve
DK98202021T DK0864649T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK91202615T DK0480525T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve

Country Status (9)

Country Link
EP (2) EP0864649B1 (da)
JP (2) JP3189212B2 (da)
AT (2) ATE324451T1 (da)
AU (1) AU649482B2 (da)
CU (1) CU22290A1 (da)
DE (2) DE69133525T8 (da)
DK (2) DK0480525T3 (da)
ES (2) ES2129025T3 (da)
GR (1) GR3029582T3 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033832A1 (en) * 1994-06-09 1995-12-14 Centro De Ingenieria Genetica Y Biotecnologia Recombinant single chain fv antibody fragment and its use in the immunopurification of the recombinant hepatitis b virus surface antigen
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
EP1403274A1 (en) * 2002-09-30 2004-03-31 Meristem Therapeutics Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
JP4936272B2 (ja) * 2006-02-13 2012-05-23 独立行政法人科学技術振興機構 バイオナノカプセルの効率的な精製法
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
MX2018011793A (es) 2016-03-31 2018-12-17 Ct Ingenieria Genetica Biotecnologia Composicion farmaceutica que comprende los antigenos de la superficie y de la nucleocapsida del virus de la hepatitis b.
KR102630293B1 (ko) * 2021-06-21 2024-01-29 선지호 박스 포장 테이프 절단용 칼날유닛과 이를 이용한 박스 포장 테이프 절단장치.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ATE91304T1 (de) * 1987-02-27 1993-07-15 Merck & Co Inc Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
IL89991A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of hepatitis b pres2 protein in methylotrophic yeasts
KR900008591B1 (ko) * 1988-05-13 1990-11-26 동아제약 주식회사 항이디오형 항체를 용출제로 사용하는 면역친화성 크로마토그라프법에 의한 생리활성물질의 정제방법

Also Published As

Publication number Publication date
JP2001231582A (ja) 2001-08-28
DE69133525T8 (de) 2007-03-08
DE69130724T2 (de) 1999-06-17
JPH0576370A (ja) 1993-03-30
ATE324451T1 (de) 2006-05-15
ES2264183T3 (es) 2006-12-16
CU22290A1 (es) 1995-01-31
EP0480525A2 (en) 1992-04-15
DE69133525T2 (de) 2006-11-23
ATE175445T1 (de) 1999-01-15
EP0864649A2 (en) 1998-09-16
JP3189212B2 (ja) 2001-07-16
AU8557491A (en) 1992-04-30
EP0480525B1 (en) 1999-01-07
ES2129025T3 (es) 1999-06-01
GR3029582T3 (en) 1999-06-30
JP3242640B2 (ja) 2001-12-25
AU649482B2 (en) 1994-05-26
EP0864649B1 (en) 2006-04-26
EP0480525A3 (en) 1992-09-30
DE69133525D1 (de) 2006-06-01
DK0480525T3 (da) 1999-08-30
EP0864649A3 (en) 1998-11-11
DE69130724D1 (de) 1999-02-18

Similar Documents

Publication Publication Date Title
DK0864649T3 (da) Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat
DE69433971D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
DE3280284D1 (de) Herstellung von oberflaechen-hepatitis-b-antigen in hefe.
EP0484787A3 (en) Hcv-specific peptides, process for obtaining them and their use
PL279426A1 (en) Method of intensifying generation of antigenic hbv particles containing essentially s and pre s2 proteins
DK345685D0 (da) Hepatitis b vaccine
DK57284A (da) Fremgangsmaade til inaktivering af et lipidvirus
DK0425082T3 (da) Vacciner
EP0250253A3 (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
EP0198299A3 (en) A process for preparing hepatitis b surface antigen containing particles in novel forms which are highly immunogenic
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
DK0412766T3 (da) Peptidfragmenter af HIV
DK1115420T3 (da) Behandling af hepatitis B med thymosin-alpha-1 og lamivudin
DK0492500T3 (da) Protektive Plasmodium falciparum-hybridproteiner, der indeholder delsekvenser af malaria-antigenerne HRPII og SERP
DE60229126D1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
DK645687D0 (da) Fremgangsmaade til fremstilling af en vaccine mod hepatitis b og den opnaaede vaccine
DE69104012D1 (de) Rekombiniebares Hepatitis-Delta-Antigen, Verfahren zu seiner Reinigung und Verwendung.
EP0293201A3 (en) Method of vaccination for hepatitis b virus
DK43991D0 (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
DK123288A (da) Fremgangsmaade til remsning af rekombinant hepatitis b overfladeantigen
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis
TH3773A (th) วัคซีนป้องกันมาเลเรีย
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
TH3773EX (th) วัคซีนป้องกันมาเลเรีย